Drugs / Immediate Release Amphetamine salt
Immediate Release Amphetamine salt
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00928148 Comparator | Jun → Nov 2004 | attention deficit-hyperactivity disorder | Shire | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immediate Release Amphetamine salt | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00928148 ↗ |
| Known as | immediate-release MAS | “The objective of this paper was to evaluate the efficacy, duration of effect, and tolerability of SHP465 mixed amphetamine salts (MAS) extended-release versus placebo and...” PMID 29809075 ↗ Jun 2018 |
| Known as | MAS IR | “The objective of this paper was to evaluate the efficacy, duration of effect, and tolerability of SHP465 mixed amphetamine salts (MAS) extended-release versus placebo and...” PMID 29809075 ↗ Jun 2018 |